Forecast

Buy	1
Hold	0
Sell	0

News Go to news feed

ALK-Abelló beats Q4 expectations and proposes dividend

ALK-Abelló reports Q4 revenue of DKK 1.73bn (3% above consensus) and EBIT of DKK 387m (5% above consensus). The EBIT margin rose to 22.3%, but net profit fell short of expectations due to higher taxes. The company proposes a dividend of DKK 1.60 per share for the first time since 2017 and expects 2026 revenue growth of 11–15% (DKK 6.9–7.2bn) with an EBIT margin of around 25%. ALK-Abelló also announced the resignation of its head of research & development and has begun the search for a successor. » More on de.investing.com
Alk-Abello A-S discloses quarterly figures for end of December

Alk-Abello A-S reports on the quarter to 31.12.2025 on 20.02.2026. One analyst expects EPS of 1.30 DKK versus 0.770 DKK in the year-ago quarter. Four analysts see revenue at an average of 1.71 billion DKK, up 13.81 percent from 1.50 billion DKK. For the fiscal year analysts on average forecast EPS of 5.63 DKK (prior year 3.68 DKK) on revenue of 6.27 billion DKK (prior year 5.54 billion DKK). » More on finanzen.net

Historical dividends Dividends

All dividend metrics All metrics

In 2026, ALK-Abelló B Aktie has already paid €0.21 in dividends. The last payout was in March.

Financials

In the last quarter, ALK-Abelló B Aktie had revenue of €239.29M and net profit of €45.19M

(EUR)	Jun 2026	YoY
Revenue	239.29M	16.91%
Gross profit	159.31M	19.45%
Net profit	45.19M	28.20%
EBITDA	70.79M	17.36%

Fundamentals

Metric	Value
Market capitalization	€6.59B
Number of shares	201.33M
52-week high/low	€35.09 - €24.99
Dividend yield	0.76%
Dividends TTM	€0.21
Beta	0.71
P/E ratio	34.20
PEG ratio	1.02
P/B ratio	6.67
P/S ratio	6.77

Company profile

ALK-Abelló A/S ist als Unternehmen für Allergielösungen in Europa, Nordamerika und international tätig. Das Unternehmen bietet Produkte für die Allergie-Immuntherapie in Form von Injektionen, sublingualen Tropfen und Tabletten für die Behandlung verschiedener Allergien an, darunter Hausstaubmilben, Gräser, Bäume, Ambrosia und japanische Zedern. Es bietet auch Adrenalin-Autoinjektoren für die Behandlung schwerer allergischer Reaktionen an und stellt Produkte für die Diagnose von Allergien her. Das Unternehmen bietet GRAZAX, RAGWITEK, RAGWIZAX, MITICURE, ODACTRA, CEDARCURE und ITULAZAX für die Behandlung von allergischer Rhinitis sowie ACARIZAX für die Behandlung von allergischer Rhinitis und allergischem Asthma an. ALK-Abelló A/S wurde 1923 gegründet und hat seinen Hauptsitz in Hørsholm, Dänemark.

Name	ALK-Abelló B Aktie
CEO	Peter Halling
Headquarters	Horsholm, cr Denmark
Website	alk.net
Sector	Health Care
Industry	Pharmaceuticals
IPO	03/10/2000
Employees	2,721